Multiple myeloma and its therapies: to what extent do they contribute to the increased incidence of second malignant neoplasms?

References

• Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Varkonyi J, Kovalszky I, Nemeth A, et al. Increased risk for cancer in multiple myeloma patients and their first-degree relatives. Haematologia (Budap) 2001;31:45-50 [a population study reporting a 40-fold increased incidence of second cancers in myeloma patients and their first-degree relatives]
   PubMedGoogle Scholar
• Law IP, Blom J. Second malignancies in patients with multiple myeloma. Oncology. 1977;34:20-4
   PubMed Web of Science ®Google Scholar
• Lynch HT, Sanger WG, Pirruccello S, et al. Familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst 2001;93:1479-83
   PubMed Web of Science ®Google Scholar
• Grosbois B, Jego P, Attal M, et al. Familial multiple myeloma: report of fifteen families. Br J Haematol 1999;105:768-70
   PubMed Web of Science ®Google Scholar
• Vachon CM, Kyle RA, Therneau TM, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 2009;114:785-90
   PubMed Web of Science ®Google Scholar
• Landgren O, Kristinsson SY, Goldin LR, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 2009;114:791-5
   PubMed Web of Science ®Google Scholar
• Landgren O, Linet MS, McMaster ML, et al. Familial characteristics of autoimmune and hematologic disorders in 8406 multiple myeloma patients: a population-based case-control study. Int J Cancer 2006;118:3095-8
   PubMed Web of Science ®Google Scholar
• Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8
   PubMed Web of Science ®Google Scholar
• Hemminki K, Vaittinen P. Effect of paternal and maternal cancer on cancer in the offspring: a population-based study. Cancer Epidemiol Biomarkers Prev 1997;6:993-7
   PubMed Web of Science ®Google Scholar
• Lynch HT, Brand RE, Hogg D, et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 2002;94:84-96
   PubMed Web of Science ®Google Scholar
• Buda G, Orciuolo E, Galimberti S, et al. Unusual association of endometrial cancer and multiple myeloma. Gynecol Oncol 2008;110:265-6
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Reale MA, Bauer F. Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide. Leuk Res 2010;34:e178-80 [the first report in the literature linking the use of lenalidomide in multiple myeloma with the occurrence of a second malignancy such as mantle cell lymphoma]
   PubMed Web of Science ®Google Scholar
• Takkouche B, Regueira-Méndez C, et al. Risk of cancer among hairdressers and related workers: a meta-analysis. Int J Epidemiol 2009;38:1512-31
   PubMed Web of Science ®Google Scholar
• Rollison DE, Helzlsouer KJ, Pinney SM. Personal hair dye use and cancer: a systematic literature review and evaluation of exposure assessment in studies published since 1992. Toxicol Environ Health B Crit Rev 2006;9:413-39
   PubMedGoogle Scholar
• Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem 2008;114:71-83
   PubMedGoogle Scholar
• Alexander DD, Mink PJ, Adami HO, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 2007;120(Suppl 12):40-61
   PubMed Web of Science ®Google Scholar
• Baris D, Silverman DT, Brown LM, et al. Occupation, pesticide exposure and risk of multiple myeloma. Scand J Work Environ Health 2004;30:215-22
   PubMed Web of Science ®Google Scholar
• Ichimaru M, Ishimaru T, Mikami M, et al. Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950–76: relationship to radiation dose absorbed by marrow. J Natl Cancer Inst 1982;69:323-8
   PubMed Web of Science ®Google Scholar
• Iwanaga M, Tagawa M, Tsukasaki K, et al. Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors. Blood 2009;113:1639-50
   PubMed Web of Science ®Google Scholar
• Lewis EB. Leukemia, multiple myeloma, and aplastic anemia in American radiologists. Science 1963;142:1492-4
   PubMed Web of Science ®Google Scholar
• Stebbings JH, Lucas HF, Stehney AF. Mortality from cancers of major sites in female radium dial workers. Am J Ind Med 1984;5:435-59
   PubMed Web of Science ®Google Scholar
• Cuzick J. Radiation-induced myelomatosis. N Engl J Med 1981;304:204-10
   PubMed Web of Science ®Google Scholar
• Brown LM, Gridley G, Check D, et al. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008;111:3388-94
   PubMed Web of Science ®Google Scholar
• Lee KM, Baris D, Zhang Y, et al. Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut. Am J Hematol 2010;85:560-3
   PubMed Web of Science ®Google Scholar
• Pratt G, Godyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007;138:563-79
   PubMed Web of Science ®Google Scholar
• Nakase K, Tsuji K, Tamaki S, et al. Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detect Prev 2005;29:256-9
   PubMedGoogle Scholar
• Dasanu CA. Immune alterations in untreated and treated multiple myeloma. J Oncol Pharm Pract 2012;18:257-63 [a recent review exploring the immune disturbances in both untreated and treated multiple myeloma patients; this review points out the potential role of lenalidomide in generation of the second cancer excess]
   Google Scholar
• Mellstedt H, Holm G, Pettersson D, et al. T cells in monoclonal gammopathies. Scand J Haematol 1982;29:57-64
   PubMedGoogle Scholar
• Schütt P, Brandhorst D, Stellberg W, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma. 2006;47:1570-82 [an important study demonstrating both cellular and humoral immunodeficiencies in multiple myeloma]
   PubMed Web of Science ®Google Scholar
• Tienhaara A, Pelliniemi TT. Peripheral blood lymphocyte subsets in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Lab Haematol 1994;16:213-23
   PubMedGoogle Scholar
• Cannon MJ, Flanders WD, Pellett PE. Occurrence of primary cancers in association with multiple myeloma and Kaposi’s sarcoma in the United States, 1973–1995. Int J Cancer 2000;85:453-6
   PubMed Web of Science ®Google Scholar
• Rettig MB, Ma HJ, Vescio RA, et al. Kaposi’s sarcoma-associated herpes virus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997;276:1851-4
   PubMed Web of Science ®Google Scholar
• Chauhan D, Bharti A, Raje N, et al. Detection of Kaposi’s sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. Blood 1999;93:1482-6
   PubMed Web of Science ®Google Scholar
• Said JW, Rettig MR, Heppner K, et al. Localization of Kaposi’s sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma. Blood 1997;90:4278-82
   PubMed Web of Science ®Google Scholar
• Todolí Parra JA, Campo López C, Segura Huerta A, et al. Association of multiple myeloma and solid neoplasms: analysis of 13 cases. Rev Clin Esp 1999;199:725-8 [a population study reporting an increased incidence of a variety second solid cancers in myeloma patients]
   PubMed Web of Science ®Google Scholar
• Kaneko S, Yamaguchi N. Epidemiological analysis of site relationships of synchronous and metachronous multiple primary cancers in the National Cancer Center, Japan, 1962–1996. Jpn J Clin Oncol 1999;29:96-105 [a large population study showing an increased incidence of gastric cancer in myeloma patients from Japan]
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Bjorkholm M, Goldin LR, et al. Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 2009;125:2147-50
   PubMed Web of Science ®Google Scholar
• Stegman R, Alexanian R. Solid tumors in multiple myeloma. Ann Intern Med 1979;90:780-2
   PubMed Web of Science ®Google Scholar
• Chin CK, Smith LL, Wright CS, et al. Multiple myeloma associated with a 9S IgG paraprotein and carcinoma of the prostate. Cancer 1972;30:206-13
   PubMed Web of Science ®Google Scholar
• Eriksson M, Hållberg B. Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case–control study. Cancer Causes Control 1992;3:63-7
   PubMed Web of Science ®Google Scholar
• Lynch HT, Ferrara K, Barlogie B, et al. Familial myeloma. N Engl J Med 2008;359:152-7
   PubMed Web of Science ®Google Scholar
• Pérez López ME, García Mata J, García Gómez J, et al. Prostate adenocarcinoma and synchcronous multiple myeloma: a case report. Actas Urol Esp 2007;31:157-9
   PubMedGoogle Scholar
• Albright LA, Schwab A, Camp NJ, et al. Population-based risk assessment for other cancers in relatives of hereditary prostate cancer (HPC) cases. Prostate 2005;64:347-55 [a study reporting an increased risk of multiple myeloma in patients with hereditary prostate cancer and their relatives]
   PubMed Web of Science ®Google Scholar
• Curtis RE, Boice JD Jr, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992;326:1745-51
   PubMed Web of Science ®Google Scholar
• Levi F, Te VC, Randimbison L, et al. Cancer risk in women with previous breast cancer. Ann Oncol 2003;14:71-3
   PubMed Web of Science ®Google Scholar
• Pruneri G, Cinieri S, Peccatori F, et al. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 2. Plasma cell myeloma coexisting with metastatic breast carcinoma in the bone marrow. J Clin Oncol 2005;23:232-3
   PubMed Web of Science ®Google Scholar
• Dörffel WV, Reitzig P, Dörffel Y, et al. Secondary malignant neoplasms in patients with breast cancer. Zentralbl Gynakol 2000;122:419-27 [a study showing an increased risk for multiple myeloma in patients with breast cancer]
   PubMedGoogle Scholar
• Coleman EA, Lynch H, Enderlin C. Initial report of a family registry of multiple myeloma. Cancer Nurs 2009;32:456-64
   PubMed Web of Science ®Google Scholar
• Dilworth D, Liu L, Stewart K, et al. Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood 2000;95:1869-71
   PubMed Web of Science ®Google Scholar
• Scélo G, Boffetta P, Autier P, et al. Associations between ocular melanoma and other primary cancers: an international population-based study. Int J Cancer 2007;120:152-9 [a study showing an increased risk for multiple myeloma in patients with ocular melanoma]
   PubMed Web of Science ®Google Scholar
• Larson AA, Leachman SA, Eliason MJ, et al. Population-based assessment of non-melanoma cancer risk in relatives of cutaneous melanoma probands. J Invest Dermatol 2007;127:183-8 [a study showing an increased risk for multiple myeloma in relatives of patients with melanoma]
   PubMed Web of Science ®Google Scholar
• Lorenzo Bermejo J, Rawal R, Hemminki K. Familial association of specific histologic types of ovarian malignancy with other malignancies. Cancer 2004;100:1507-14
   PubMed Web of Science ®Google Scholar
• Hemminki K. Re: familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst 2002;94:462-3
   PubMed Web of Science ®Google Scholar
• Stratton JF, Thompson D, Bobrow L, et al. The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. Am J Hum Genet 1999;65:1725-32 [a study reporting a relative risk of 10 for multiple myeloma patients in ovarian cancer patients]
   PubMed Web of Science ®Google Scholar
• Zighelboim I, Babb S, Gao F, et al. Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility. Gynecol Oncol 2007;105:390-4 [a study reporting on a highly increased risk for multiple myeloma in patients with endometrial adenocarcinoma and their relatives]
   PubMed Web of Science ®Google Scholar
• Spurdle A, Webb P. Australian National Endometrial Cancer Study. Re: excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility. Gynecol Oncol 2008;109:153
   PubMed Web of Science ®Google Scholar
• Subramanian S, Goldstein DP, Parlea L, et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 2007;17:1277-88
   PubMed Web of Science ®Google Scholar
• Stein M, Lachter J, Bartal A, et al. Thyroid cancer and multiple primary malignancies in Israel. J Surg Oncol 1997;47:221-4
   Google Scholar
• Kristinsson SY, Goldin LR, Björkholm M, et al. Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance. Haematologica 2009;94:1179-81 [a study exploring the risk of second malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance]
   PubMed Web of Science ®Google Scholar
• Plna K, Hemminki K. Familial bladder cancer in the National Swedish Family Cancer Database. J Urol 2001;166:2129-33
   PubMed Web of Science ®Google Scholar
• Gisserot O, de Jaureguiberry JP, Ribeil JA, et al. Cerebral glioblastoma complicating the course of myeloma. Presse Med 1997;26:1197
   PubMed Web of Science ®Google Scholar
• González Silva M. Second neoplasm in a patient diagnosed with IgD myeloma. Presentation of a case and review of the literature. Sangre (Barc) 1993;38:47-9
   PubMedGoogle Scholar
• Howard RA, Dores GM, Curtis RE, et al. Merkel cell carcinoma and multiple primary cancers. Cancer Epidemiol Biomarkers Prev 2006;15:1545-9
   PubMed Web of Science ®Google Scholar
• Christou L, Tsiara S, Frangides Y, et al. Patients with multiple myeloma and solid tumors: six case reports. J Exp Clin Cancer Res 1998;17:239-42
   PubMed Web of Science ®Google Scholar
• Marinopoulos S, Skorda L, Karatapanis S, et al. A Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer. Med Oncol 2008;25:415-18
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Baz RC, McFadden CM, et al. An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. BJU Int 2008;101:712-15
   PubMed Web of Science ®Google Scholar
• Cooper GL, Shaffer DW, Raval HB. Fine-needle aspiration biopsy of multiple myeloma in a patient with renal-cell carcinoma: a case report. Diagn Cytopathol 1993;9:551-4
   Google Scholar
• Yamada O, Naito T, Shimazaki M, et al. A case of multiple myeloma complicated with early gastric cancer and early sigmoid colon cancer. Nippon Shokakibyo Gakkai Zasshi 1993;90:1432-6
   PubMedGoogle Scholar
• Dong C, Hemminki K. Second primary neoplasms among 53,159 haematolymphoproliferative malignancy patients in Sweden, 1958–1996: a search for common mechanisms. Br J Cancer 2001;85:997-1005
   PubMed Web of Science ®Google Scholar
• Luca DC, Almanaseer IY. Simultaneous presentation of multiple myeloma and acute monocytic leukemia. Arch Pathol Lab Med 2003;127:1506-8
   PubMed Web of Science ®Google Scholar
• Pasqualetti P, Colantonio D, Casale R, et al. Simultaneous presentation of multiple myeloma and acute myelomonocytic leukemia in the absence of previous chemotherapy. Description of a case and review of the literature. Minerva Med 1990;81:487-93
   PubMedGoogle Scholar
• Parapia L, Abbott CR, Masters G, et al. Simultaneous presentation of acute myelomonocytic leukaemia and multiple myeloma. Acta Haematol 1982;68:153-6
   PubMed Web of Science ®Google Scholar
• Pasqualetti P, Colantonio D, Casale R, et al. Simultaneous presentation of multiple myeloma and acute myelomonocytic leukemia in the absence of previous chemotherapy. Description of a case and review of the literature. Minerva Med 1990;81:487-93
   PubMedGoogle Scholar
• Nagura E, Kawashima K, Yamada K. Multiple primary cancers associated with hematological malignancies. Jpn J Clin Oncol 1985;15(Suppl 1):211-22
   PubMedGoogle Scholar
• Iwakiri R, Mikoshiba M, Tsutsumi H, et al. A case of malignant lymphoma concomitant with multiple myeloma. Nippon Ronen Igakkai Zasshi 2001;38:678-81
   PubMedGoogle Scholar
• Hewamana S, Pepper C, Couzens S, et al. IgM multiple myeloma: a diagnostic challenge in a patient with coexisting chronic lymphocytic leukaemia. Int J Hematol 2008;88:424-7
   PubMed Web of Science ®Google Scholar
• Shpilberg O, Mark Z, Biniaminov M, et al. Transformation of chronic lymphocytic leukemia to multiple myeloma: clonal evolution of second malignancy? Leukemia 1995;9:1974-8
   PubMed Web of Science ®Google Scholar
• Robak, T. Second malignancies and Richter’s syndrome in patients with chronic lymphocytic leukemia. Hematology 2004;9:387-400
   PubMedGoogle Scholar
• Strobel ES, Bauchmüller K, Schmitt-Gräff A, et al. Occurrence of multiple myeloma 13 years after Hodgkin’s disease: chance or consequence? Ann Hematol 2005;84:830-2
   PubMed Web of Science ®Google Scholar
• Brumana N, Scheidler D, Bonato M, et al. Peripheral T cell lymphoma associated with multiple myeloma. Haematologica 1993;78:335-7
   PubMed Web of Science ®Google Scholar
• Qian YW, Siegel D, Bhattacharyya P. Multiple skin lesions in a patient with multiple myeloma. CD30-positive cutaneous large cell lymphoproliferative disorder. Arch Pathol Lab Med 2006;130:e41-3
   PubMedGoogle Scholar
• Cartron G, Roingeard P, Benboubker L, et al. Sezary syndrome in a patient with multiple myeloma: demonstration of a clonally distinct second malignancy. Eur J Haematol 1999;63:354-7
   PubMed Web of Science ®Google Scholar
• Barzilai A, Trau H, David M, et al. Mycosis fungoides associated with B-cell malignancies. Br J Dermatol 2006;155:379-86
   PubMed Web of Science ®Google Scholar
• Saif MW, Greenberg BR. Multiple myeloma and hairy cell leukemia: a rare association or coincidence? Leuk Lymphoma 2001;42:1043-8
   PubMed Web of Science ®Google Scholar
• Nowakowska-Kopera A, Wójcik M, Rudzki Z, et al. Concomitant myeloid sarcoma and plasma cell myeloma – case report of a hitherto undescribed association of two neoplasms. Pol Merkur Lekarski 2007;23:120-3
   PubMedGoogle Scholar
• Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute leukemia associated with alkylating agents. Arch Intern Med 1975;135:185-92
   PubMed Web of Science ®Google Scholar
• Natori K, Izumi H, Kaneko K, et al. Four cases of therapy-related leukemia in multiple myeloma. Gan To Kagaku Ryoho 2007;34:121-4
   PubMedGoogle Scholar
• Sonoda Y, Kumabe T, Umezawa K, et al. Rapid growth of glioblastoma during therapy for multiple myeloma: case report. No Shinkei Geka 1998;26:737-41
   PubMedGoogle Scholar
• Rowley JD. The role of chromosome translocations in leukemogenesis. Semin Hematol 1999;36:59-72
   PubMed Web of Science ®Google Scholar
• Yuan ZG, Dun XY, Li YH, et al. Treatment of multicentric Castleman’s Disease accompanying multiple myeloma with bortezomib: a case report. J Hematol Oncol 2009;2:19
   PubMed Web of Science ®Google Scholar
• Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med 2011;365:2241-2
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Cavalli M, et al. A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens. Blood 2010;116:622
   Web of Science ®Google Scholar